Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.44 |
| ▸ | WNT3A | P56704 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3703151 | 0.83 | RAB9A (0.49) | SMN1; SMN2CYP1A2CYP2C19KMT2AMEN1 | |
| SCHEMBL933753 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2CYP1A2CYP2C19KMT2AMEN1 | |
| SCHEMBL933781 | 0.80 | KDM4E (0.51) | SMN1; SMN2CYP1A2CYP2C19KMT2AMEN1 | |
| SCHEMBL1733676 | 0.76 | CYP19A1 (0.55) | SMN1; SMN2CYP1A2CYP2C19CTNNB1WNT3A | |
| SCHEMBL3703417 | 0.74 | KDM4E (0.53) | SMN1; SMN2CYP1A2CYP2C19KMT2AMEN1 | |
| SCHEMBL30134679 | 0.73 | MAPT (0.61) | SMN1; SMN2CYP1A2CYP2C19KMT2AMEN1 | |
| SCHEMBL3702884 | 0.73 | KDM4E (0.44) | SMN1; SMN2CYP1A2CYP2C19KMT2AMEN1 | |
| SCHEMBL787766 | 0.73 | MAPT (0.61) | SMN1; SMN2CYP1A2CYP2C19KMT2AMEN1 | |
| SCHEMBL7085670 | 0.72 | SMN1; SMN2 (0.51) | SMN1; SMN2CYP1A2CYP2C19CTNNB1WNT3A | |
| SCHEMBL3696044 | 0.71 | RAB9A (0.61) | SMN1; SMN2CYP1A2CYP2C19KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173424-B2 | Pyridine derivatives with umami flavour | GIVAUDAN S.A. (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9173424-B2 | Pyridine derivatives with umami flavour | GIVAUDAN S.A. (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9173424-B2 | Pyridine derivatives with umami flavour | GIVAUDAN S.A. (CH) | 2015-11-03 | — | — | US | disclosed |
| US-20140295045-A1 | Pyridine Derivatives With Umami Flavour | GIVAUDAN S.A. (CH) | 2014-10-02 | — | — | US | disclosed |
| US-20140295045-A1 | Pyridine Derivatives With Umami Flavour | GIVAUDAN S.A. (CH) | 2014-10-02 | — | — | US | disclosed |
| US-20140295045-A1 | Pyridine Derivatives With Umami Flavour | GIVAUDAN S.A. (CH) | 2014-10-02 | — | — | US | disclosed |
| EP-2451781-B1 | PYRIDINE DERIVATIVES WITH UMAMI FLAVOUR | GIVAUDAN SA (CH) | 2013-09-18 | — | — | EP | disclosed |
| EP-2451781-B1 | PYRIDINE DERIVATIVES WITH UMAMI FLAVOUR | GIVAUDAN SA (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20120121783-A1 | Pyridine Derivatives With Umami Flavour | GIVAUDAN SA (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120121783-A1 | Pyridine Derivatives With Umami Flavour | GIVAUDAN SA (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120121783-A1 | Pyridine Derivatives With Umami Flavour | GIVAUDAN SA (CH) | 2012-05-17 | — | — | US | disclosed |
| WO-2011004016-A1 | PYRIDINE DERIVATIVES WITH UMAMI FLAVOUR | GIVAUDAN SA (CH) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121783-A1 | Pyridine Derivatives With Umami Flavour | C5, CHRM1, C9 | SMN1; SMN2 2443/4885CYP1A2 1200/4885CYP2C19 629/4885 |
| US-20140295045-A1 | Pyridine Derivatives With Umami Flavour | C5, CHRM1, C9 | SMN1; SMN2 2134/4885CYP1A2 1583/4885CYP2C19 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.